Moderna and Merck said on Tuesday their experimental personalized vaccine continued to cut the risk of death or recurrence of ...

The firm is expecting a slew of key readouts for mRNA vaccines for treating cancer and rare diseases and is exploring vaccines for autoimmune conditions.

Moderna Inc.’s chairman says the Trump administration’s vaccine policy changes are part of a broader attack on science that ...

Moderna said on Monday it expects to report around $1.9 billion in sales for 2025, putting it near the upper end of its ...

Moderna shares rose after the company posted a narrower third-quarter loss than Wall Street expected, a sign that its cost-cutting measures are helping offset the decline of its COVID business. The ...